Silfat Azam, Abdalla Khalil and Ahmad Taha. Guillain-Barré Syndrome in a 67-year-old Male Post COVID-19 Vaccination (Astra Zeneca).
. 2021; 9(8):424-427. doi: 10.12691/AJMCR-9-8-10
COVID-19 infection, COVID-19 vaccine, Guillain-Barre Syndrome (GBS), Miller Fisher Syndrome (MFS)
This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit
[1] | Kuwabara S, Yuki N. Axonal Guillain-Barré syndrome: concepts and controversies. Lancet Neurol. 2013 Dec; 12(12): 1180-8. |
|
[2] | Brannagan TH 3rd, Zhou Y. HIV-associated Guillain-Barré syndrome. J Neurol Sci. 2003 Apr 15; 208(1-2): 39-42. |
|
[3] | Lehmann HC, Hartung HP, Kieseier BC, Hughes RA. Guillain-Barré syndrome after exposure to influenza virus. Lancet Infect Dis. 2010 Sep; 10(9): 643-51. |
|
[4] | Steininger C, Popow-Kraupp T, Seiser A, Gueler N, Stanek G, Puchhammer E. Presence of cytomegalovirus in cerebrospinal fluid of patients with Guillain-Barre syndrome. J Infect Dis. 2004 Mar 15; 189(6): 984-9. |
|
[5] | Toscano G, Palmerini F, Ravaglia S, Ruiz L, Invernizzi P, Cuzzoni MG, Franciotta D et al. Guillain-Barré Syndrome Associated with SARS-CoV-2. N Engl J Med. 2020 Jun 25; 382(26): 2574-2576 |
|
[6] | Webb S, Wallace VC, Martin-Lopez D, Yogarajah M. Guillain-Barré syndrome following COVID-19: a newly emerging post-infectious complication. BMJ Case Rep. 2020 Jun 14; 13(6): e236182. |
|
[7] | Shoamanesh A, Chapman K, Traboulsee A. Postvaccination Miller Fisher syndrome. Arch Neurol. 2011 Oct; 68(10): 1327-9. |
|
[8] | Rees JH, Thompson RD, Smeeton NC, Hughes RA. Epidemiological study of Guillain-Barré syndrome in south east England. J Neurol Neurosurg Psychiatry. 1998 Jan; 64(1): 74-7. |
|
[9] | Doets AY, Verboon C, van den Berg B, Harbo T, Cornblath DR, Willison HJ, et al. Regional variation of Guillain-Barré syndrome. Brain. 2018 Oct 1; 141(10): 2866-2877. |
|
[10] | Anandan C, Khuder SA, Koffman BM. Prevalence of autonomic dysfunction in hospitalized patients with Guillain-Barré syndrome. Muscle Nerve. 2017 Aug; 56(2): 331-333. |
|
[11] | Yuki N, Hartung HP. Guillain-Barré syndrome. N Engl J Med. 2012 Jun 14; 366(24): 2294-304. |
|
[12] | McCarthy N, Giesecke J. Incidence of Guillain-Barré syndrome following infection with Campylobacter jejuni. Am J Epidemiol. 2001 Mar 15; 153(6): 610-4. |
|
[13] | Rahimi K. Guillain-Barre syndrome during COVID-19 pandemic: an overview of the reports. Neurol Sci. 2020 Nov; 41(11): 3149-3156. |
|
[14] | Salmon DA, Proschan M, Forshee R, Gargiullo P, Bleser W, Burwen DR et al. H1N1 GBS Meta-Analysis Working Group. Association between Guillain-Barré syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis. Lancet. 2013 Apr 27; 381(9876): 1461-8. |
|
[15] | Hughes RA, Charlton J, Latinovic R, Gulliford MC. No association between immunization and Guillain-Barré syndrome in the United Kingdom, 1992 to 2000. Arch Intern Med. 2006 Jun 26; 166(12): 1301-4. |
|
[16] | Sadia Waheed, Angel Bayas, Fawzi Hindi, Zufe Rizvi, Patricio S. Espinosa. Neurological Complications of COVID-19: Guillain-Barre Syndrome Following Pfizer COVID-19 Vaccine. Cureus 13(2): e13426. |
|
[17] | https://www.ema.europa.eu/en/news/covid-19-vaccine-astrazeneca-prac-preliminary-view-suggests-no-specific-issue-batch-used-austria. |
|